CHO YONGJIN | Oncology | Best Researcher Award

Dr. CHO YONGJIN | Oncology | Best Researcher Award

Dept. of Orthopedic Surgery, at Chosun University Hospital, South Korea.

Dr. Yongjin Cho is an Associate Professor in the Department of Orthopaedic Surgery at Chosun University College of Medicine. With a rich academic and professional journey spanning over two decades, Dr. Cho specializes in orthopedic surgery, musculoskeletal oncology, and pediatric orthopedics. He is recognized for his innovative contributions to trauma and sarcoma management and has published extensively in high-impact journals. In addition to his clinical expertise, Dr. Cho is actively involved in medical robotics research, emphasizing its potential in surgical advancements. His dedication to education, research, and patient care highlights his standing as a distinguished professional in orthopedics.

Profile

Scopus

Education ๐ŸŽ“

Dr. Choโ€™s academic background reflects his dedication to interdisciplinary excellence:

  • B.Eng. (Industrial Engineering) โ€“ Chonnam National University, 1995.
  • B.Med. (Medicine) โ€“ Chonnam National University, 2000.
  • M.Med. (Orthopaedics) โ€“ Chonnam National University, 2008.
  • Ph.D. (Medicine) โ€“ Chonnam National University, 2016.

His advanced training in both engineering and medicine has provided a unique perspective in integrating technology into clinical practice and research.

Professional Experience ๐Ÿฉบ

Dr. Cho began his career as an orthopedic resident at Chonnam National University Hospital (2005โ€“2009), later specializing in foot and ankle, hip, and pediatric orthopedics. He obtained his orthopedic specialty license in 2009. His roles include:

  • Fellowship Training in Foot and Ankle Surgery (2009).
  • Clinical Professor in Pediatric and Musculoskeletal Tumor Surgery (2010โ€“2011).
  • Assistant Professor at Yonsei Severance Sinchon Hospital (2011โ€“2015).
  • Associate Professor at Chosun University (2018โ€“present).

Dr. Cho also serves as an Insurance Professional Committee Member for the Korea Musculoskeletal Oncologic Society.

Research Interests ๐Ÿ”ฌ

Dr. Choโ€™s research spans orthopedic oncology, trauma surgery, and medical robotics, with a focus on:

  • Innovative surgical techniques for sarcomas and musculoskeletal tumors.
  • Integration of robotics in orthopedic surgery.
  • Biomechanics and implant design for improved surgical outcomes.
  • Pediatric orthopedic deformities and treatments.
    His work emphasizes applying cutting-edge technologies, such as robotic systems, to enhance surgical precision and patient care.

Awards & Recognitions ๐Ÿ†

Dr. Cho has received numerous awards throughout his career, including:

  • Recognition for Excellence in Orthopedic Research from the Korean Orthopedic Association.
  • Contributions to musculoskeletal oncology recognized by the Korean Musculoskeletal Oncologic Society.
  • Awards for innovative research in medical robotics and its application in orthopedics.
    These accolades underscore his impact as a clinician, educator, and researcher.

Top Notes Publications ๐Ÿ“š

Dr. Cho has authored over 40 publications in reputable journals. Selected works include:

1.Oblique Supramalleolar Opening Wedge Osteotomy Without Fibular Osteotomy for Varus Deformity of the Ankle

  • Journal: Foot & Ankle International (2009)
  • Summary: This study focuses on a surgical technique for correcting varus deformity of the ankle without performing a fibular osteotomy. The oblique supramalleolar opening wedge osteotomy is highlighted as a less invasive method with reduced complications, maintaining joint alignment and functionality.
  • Key Findings:
    • Effective for varus ankle deformity correction.
    • Demonstrates reduced operative risks.
    • Enhances post-surgical outcomes with less recovery time.
  • Relevance: Important for orthopedic surgeons exploring minimally invasive techniques for lower extremity deformities.

2. Prognostic Implications of Polycomb Proteins in Sarcoma

  • Journal: BMC Cancer (2018)
  • Summary: This research evaluates the role of Polycomb group (PcG) proteins in the prognosis of sarcoma. It investigates the molecular pathways influenced by PcG proteins and their impact on tumor behavior, aggressiveness, and patient survival.
  • Key Findings:
    • Overexpression of PcG proteins correlates with poor prognosis in sarcoma.
    • PcG proteins influence tumor proliferation, migration, and resistance to therapy.
    • Provides a foundation for potential therapeutic targeting of PcG pathways.
  • Relevance: Crucial for oncology researchers and clinicians focusing on molecular biomarkers and targeted therapy for sarcoma.

3. HMB45-Negative Intramuscular Angiomyolipoma: A Case Report and Review

  • Journal: Bahrain Medical Bulletin (2021)
  • Summary: This case report describes a rare presentation of HMB45-negative intramuscular angiomyolipoma, providing diagnostic challenges and insights into its pathology. It reviews similar cases to outline management strategies for this unique subtype of angiomyolipoma.
  • Key Findings:
    • HMB45-negative cases present diagnostic difficulty due to the absence of a typical immunohistochemical marker.
    • Highlights the importance of morphological evaluation and differential diagnosis.
    • Discusses successful management options, including surgical resection.
  • Relevance: Valuable for pathologists and clinicians involved in diagnosing and managing rare soft tissue tumors.

4. Healthcare Robots in the New Normal Era

  • Journal: Journal of Digital Convergence (2021)
  • Summary: This article examines the growing role of healthcare robots in the “New Normal” era, especially post-COVID-19. It explores their applications, benefits, and challenges in various healthcare settings.
  • Key Findings:
    • Robots enhance efficiency in patient care, disinfection, and remote monitoring.
    • Reduced human contact minimizes infection risks in pandemics.
    • Challenges include high costs, technical limitations, and ethical considerations.
  • Relevance: Pertinent for researchers and practitioners in health informatics, robotics, and digital transformation of healthcare systems.

Conclusion

Dr. Yongjin Cho is a highly qualified candidate for the Best Researcher Award. Their comprehensive experience in orthopaedic surgery, commitment to research innovation, and significant academic contributions make them an exemplary researcher. While areas like grant acquisition, international collaborations, and public engagement could be strengthened, their current achievements are commendable and worthy of recognition. Dr. Choโ€™s work has the potential to set new benchmarks in orthopaedic research and medical robotics, reflecting excellence in advancing both clinical and academic frontiers.

 

Julio Pimente | Cancer Biology | Young Scientist Award

Dr. Julio Pimente | Cancer Biology | Young Scientist Award

Dr. Julio M. Pimentel is an accomplished cancer biologist and clinical researcher specializing in translational medicine. With a robust background in studying resistance mechanisms in cancer therapies, Dr. Pimentel has significantly contributed to understanding and overcoming resistance in triple-negative breast cancer (TNBC) and pancreatic cancer. Currently, he serves as an Institutional Research Academic Career Development Award (IRACDA) Postdoctoral Fellow at the University of California, San Diego. His work is aimed at improving cancer treatment outcomes and expanding leadership diversity in STEM fields.

Profile ๐Ÿ“„

For more details on Dr. Julio M. Pimentel’s academic and professional journey, visit his LinkedIn profile.

Education ๐ŸŽ“

Doctor of Philosophy in Cancer Biology (2023), Wayne State University School of Medicine. Dissertation: “The Mechanisms of TRAIL Resistance in Triple-Negative Breast Cancer.”

Master of Science in Clinical Investigation and Translational Medicine (2018), University of Miami Miller School of Medicine. Thesis: “Metabolic Reprogramming with Beta-Alanine to Overcome Gemcitabine Resistance in Pancreatic Cancer.”

Bachelor of Science in Biological Sciences (2014), California State University Stanislaus, with concentrations in Molecular Biology & Microbiology and a Minor in Chemistry.

Experience ๐Ÿง‘โ€๐Ÿ”ฌ

IRACDA Postdoctoral Fellow (2023-Present), University of California San Diego. Research on endothelial cytoprotective signaling.

Ph.D. Graduate Research Assistant (2019-2023), Barbara Ann Karmanos Institute & Wayne State University. Investigated mechanisms of TRAIL resistance in TNBC.

MSCTI Graduate Research Assistant (2016-2018), University of Miami & Sylvester Comprehensive Cancer Center. Focused on overcoming chemoresistance in pancreatic cancer.

Instructional Student Assistant (2012-2016), California State University Stanislaus. Tutored students in various scientific disciplines.

Licensed Nurse Aide (2012-2013), Covenant Care at Home & Emanuel Medical Center. Provided end-of-life care.

Research Interests ๐Ÿ”ฌ

Dr. Pimentel’s research interests include cancer biology, mechanisms of drug resistance, translational medicine, and immunotherapy. His work primarily focuses on identifying and targeting resistance pathways in aggressive cancers, such as TNBC and pancreatic cancer, to improve therapeutic efficacy and patient outcomes.

Awards ๐Ÿ†

UCSD Institutional Research Academic Career Development Award (2025-2023)

Leonard N. Simons Award (2023)

Oakland County Executiveโ€™s Oakland Together 40 Under 40 Class of 2023

Top 100 Innovators and Entrepreneurs by The Top 100 Magazine (2022)

National Latino Leader Award by the National Diversity Council (2021)

Publications Top Notes ๐Ÿ“š

Targeting PP2A to Overcome TRAIL Resistance in TNBC Cells (Published in Journal of Cancer Research, 2023) [Cited by 25 articles].

p62/SQSTM1 as a Critical Player in PARP Inhibitor Resistance in Triple-Negative Breast Cancer (Published in Molecular Carcinogenesis, 2022) [Cited by 18 articles].

RNA-seq Identifies Inflammatory Pathways to Confer TRAIL Resistance in TNBC Cells (Under Peer Review, 2023).